The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
Official Title: A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Study ID: NCT01462890
Brief Summary: The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months.
Detailed Description: Determination whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to 15 months
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
, Aalborg, , Denmark
, Copenhagen, , Denmark
, Herlev, , Denmark
, Kuopio, , Finland
, Oulu, , Finland
, Tampere, , Finland
, Turku, , Finland
, Angers, , France
, Besancon, , France
, Blois, , France
, Bordeaux, , France
, Caen, , France
, Cahors, , France
, Clamart, , France
, Clermont-Ferrand, , France
, Creteil, , France
, Dax, , France
, Draguignan, , France
, Grenoble, , France
, Limoges, , France
, Lyon, , France
, Mougins, , France
, Nancy, , France
, Nantes, , France
, Nice, , France
, Nimes, , France
, Orleans, , France
, Paris, , France
, Pau, , France
, Plérin, , France
, Poitiers, , France
, Quimper, , France
, Reims, , France
, Rouen, , France
, Saint-Herblain, , France
, Strasbourg, , France
, Toulouse, , France
, Vandoeuvre-Les-Nancy, , France
, Vannes, , France
, Villejuif, , France
, Aachen, , Germany
, Arnsberg, , Germany
, Aschaffenburg, , Germany
, Augsburg, , Germany
, Bad Homburg vor der Höhe, , Germany
, Berlin, , Germany
, Bochum, , Germany
, Bonn, , Germany
, Bottrop, , Germany
, Brandenburg, , Germany
, Bremen, , Germany
, Chemnitz, , Germany
, Coburg, , Germany
, Deggendorf, , Germany
, Dessau, , Germany
, Dresden, , Germany
, Düsseldorf, , Germany
, Ebersberg, , Germany
, Eggenfelden, , Germany
, Erlangen, , Germany
, Essen, , Germany
, Esslingen, , Germany
, Flensburg, , Germany
, Frankfurt/M., , Germany
, Freiburg, , Germany
, Fürstenfeldbruck, , Germany
, Fürth, , Germany
, Georgsmarienhütte, , Germany
, Gera, , Germany
, Greifswald, , Germany
, Göttingen, , Germany
, Gütersloh, , Germany
, Halle (Saale), , Germany
, Hamburg, , Germany
, Hanau am Main, , Germany
, Hannover, , Germany
, Heidelberg, , Germany
, Henstedt-Ulzburg, , Germany
, Hildesheim, , Germany
, Jena, , Germany
, Kaiserslautern, , Germany
, Karlsruhe, , Germany
, Kassel, , Germany
, Kiel, , Germany
, Krefeld, , Germany
, Köln, , Germany
, Lich, , Germany
, Limburg, , Germany
, Lübeck, , Germany
, Lüneburg, , Germany
, Magdeburg, , Germany
, Mainz, , Germany
, Mannheim, , Germany
, Marburg, , Germany
, Minden, , Germany
, München, , Germany
, Neumarkt, , Germany
, Neuss, , Germany
, Nordhausen, , Germany
, Offenbach, , Germany
, Offenburg, , Germany
, Oldenburg, , Germany
, Osnabrück, , Germany
, Ravensburg, , Germany
, Regensburg, , Germany
, Reutlingen, , Germany
, Rosenheim, , Germany
, Rostock, , Germany
, Rottweil, , Germany
, Saalfeld, , Germany
, Salzgitter, , Germany
, Schweinfurt, , Germany
, Schwäbisch Hall, , Germany
, Sigmaringen, , Germany
, Solingen, , Germany
, Stralsund, , Germany
, Stuttgart, , Germany
, Torgau, , Germany
, Trier, , Germany
, Tübingen, , Germany
, Ulm, , Germany
, Viersen, , Germany
, Wiesbaden, , Germany
, Witten, , Germany
, Wolfsburg, , Germany
, Worms, , Germany
, Bergen, , Norway
, Oslo, , Norway
, Trondheim, , Norway
, Falun, , Sweden
, Uppsala, , Sweden
Name: Jacobus Pfisterer, MD PhD
Affiliation: AGO Study Group
Role: STUDY_CHAIR